Aspira Women's Health Inc. (AWHL) company profile
Close on Oct 19, 2026Market cap $9.91MP/E –Yield –
About Aspira Women's Health
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Aspira Women’s Health Inc. develops and commercializes diagnostic tests focused on women's gynecologic health. The company specializes in the risk assessment and differential diagnosis of gynecologic diseases, primarily ovarian cancer and conditions such as endometriosis and pelvic masses. Its commercial offerings and pipeline include diagnostic solutions such as Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform, and OVAinform, as well as the Aspira Synergy platform. The company provides laboratory-developed tests through its dedicated laboratory facility, Aspira Labs.
The company operates within the United States, providing diagnostic products and clinical laboratory services to healthcare providers and patients. Aspira Women's Health maintains operating facilities in Austin, Texas, and Shelton, Connecticut. Its corporate headquarters and principal executive offices are situated in Austin, Texas.
Summary of the business section of Aspira Women's Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aspira Women's Health Inc.
- Headquarters
- Austin, TX
- Address
- 12117 Bee Caves Road Building Three, Suite 100 78738
- Phone
- (512) 519-0400
- Website
- aspirawh.com
- Employees
- 36, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, Boston, Massachusetts
Stock & identifiers
- Ticker
- AWHL
- Former tickers
- AWH until Aug 13, 2025; VRML until Aug 14, 2020
- Exchange
- OTC
- IPO date
- Oct 2, 2000
- Shares outstanding
- 47M, Aug 12, 2026
- Public float
- $4.67M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, May 12, 2023; 1-for-10 reverse, Mar 4, 2008
- SEC CIK
- 926617
- CUSIP
- 04537Y208
- ISIN
- US04537Y2081
- FIGI
- BBG000BTYP37
- Share class FIGI
- BBG001SSBCM2
- EIN
- 33-0595156
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Strahley | Chief Financial Officer | – |
| Brian Hungerford | Chief Financial Officer | – |
| Michael William Buhle | Chief Executive Officer | – |
| James C. Crawford | Vice President of Finance | – |
| Sandra Milligan | Interim CEO | 13,644 |
| Jeffrey k. cohen | Director | 457,028 |
| John D. Fraser | Director | 854,162 |
| Cynthia D. Hundorfean | Director | – |
| Ellen Beausang | Director | 6,458 |
| Winfred Parnell | Director | 71,209 |
| Jane Pine Wood | Director | – |
| Ellen O'Connor Vos | Director | 73,989 |
| John Phillip Ragard | Director | 134,734 |
| Stefanie L. Cavanaugh | Director | 78,726 |
| Jannie Prestridge Herchuk | Director | 82,502 |
| Celeste Rachelle Fralick | Director | 55,665 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Michael Buhle | $419.93K | $575.88K | $141.05K | $1 | – |
| FY2025 Nicole Sandford | $0 | $0 | $141.05K | $1 | – |
| FY2025 Sandra Milligan | $80.51K | $79.71K | $141.05K | $1 | – |
| FY2024 Michael Buhle | $0 | $0 | $173.55K | $1 | – |
| FY2024 Nicole Sandford | $1.24M | $834.85K | $173.55K | $1 | – |
| FY2024 Sandra Milligan | $358.43K | $281.76K | $173.55K | $1 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Michael Buhle Chief Executive Officer | $374.52K | $45.41K | – | $419.93K | – |
| Brian Hungerford Chief Financial Officer | – | $38.30K | $102.75K | $141.05K | – |
| Sandra Milligan, M.D., J.D. Former President, Interim Chief Executive Officer | $80.51K | – | – | $80.51K | -78% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 36 full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?